Follow the Money to Bio/Pharmaceutical Opportunities Spotlight on Fusion Pharmaceuticals, Inc.
Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
Fusion Pharmaceuticals is a private company based in Canada that develops radiotherapeutics for the treatment of cancer. It raised $21 million in a venture capital investment, as reported in the PharmSource Lead Sheet on September 28, 2017.
Corporate Highlights
- Fusion Pharmaceuticals was founded in 2014
- Corporate Headquarters: Hamilton, ON, Canada
Sourcing Opportunities
- • Fusion Pharmaceuticals plans to use the proceeds to expand its pipeline and to support the clinical development of FPX-01:
- AM0010 oFPX-01 – To initiate clinical trials in 2018:
- For treatment of refractory cancers
- Dosage Form: Parenteral
- Nature of API: Radioactive/Radiolabeled product; Biologic – Antibody – Modified
- Therapeutic Areas: Oncology – Immunotherapy; Oncoloy –Chemotherapy
- Previous Financings
- February 2017: $25 million in a completed capital investment
Pipeline
| Product Candidate | Indication | Dosage Form | Status | Next Anticipated Step |
|---|---|---|---|---|
| FPX-01 | Refractory cancers | Parenteral | Preclinical | To initiate clinical trials in early 2018 |
Contact Information
| Fusion Pharmaceuticals, Inc. | Key Officers |
|---|---|
| 1280 Main Street. West NRB-A316 | John Valliant, PhD, President & CEO |
| Hamilton, ON, L8S 4K1 Canada | Eric Burak, PhD, CSO |
| Phone: (905) 525-9140 | Istvan Molnar, MD, CMO |
| Web: http://fusionpharma.com/ | Mohan Pabba, Scientist, Protein Engineering |
Related posts:
Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ARMO BioSciences, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on CymaBay Therapeutics
Follow the Money to Pharmaceutical Opportunities – Spotlight on AveXis, Inc.
